202 related articles for article (PubMed ID: 30680526)
1. Liver disease in adults with severe alpha-1-antitrypsin deficiency.
Tanash HA; Piitulainen E
J Gastroenterol; 2019 Jun; 54(6):541-548. PubMed ID: 30680526
[TBL] [Abstract][Full Text] [Related]
2. The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.
Bernspång E; Carlson J; Piitulainen E
Scand J Gastroenterol; 2009; 44(11):1349-55. PubMed ID: 19891586
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.
Piitulainen E; Tanash HA
COPD; 2015 May; 12 Suppl 1():36-41. PubMed ID: 25938290
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?
Elzouki AN; Eriksson S
Eur J Gastroenterol Hepatol; 1996 Oct; 8(10):989-94. PubMed ID: 8930564
[TBL] [Abstract][Full Text] [Related]
5. Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden.
Tanash HA; Ekström M; Wagner P; Piitulainen E
Int J Chron Obstruct Pulmon Dis; 2016; 11():1663-9. PubMed ID: 27555756
[TBL] [Abstract][Full Text] [Related]
6. Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.
Tanash HA; Ekström M; Rönmark E; Lindberg A; Piitulainen E
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889108
[TBL] [Abstract][Full Text] [Related]
7. Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population.
Tanash H; Ekström M; Basil N; Rönmark E; Lindberg A; Piitulainen E
Int J Chron Obstruct Pulmon Dis; 2020; 15():1245-1252. PubMed ID: 32606637
[TBL] [Abstract][Full Text] [Related]
8. Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age.
Mostafavi B; Diaz S; Tanash HA; Piitulainen E
Medicine (Baltimore); 2017 Mar; 96(12):e6180. PubMed ID: 28328804
[TBL] [Abstract][Full Text] [Related]
9. Severe alpha-1-antitrypsin deficiency increases the risk of venous thromboembolism.
Basil N; Ekström M; Piitulainen E; Lindberg A; Rönmark E; Jehpsson L; Tanash H
J Thromb Haemost; 2021 Jun; 19(6):1519-1525. PubMed ID: 33763945
[TBL] [Abstract][Full Text] [Related]
10. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ).
Tanash HA; Nilsson PM; Nilsson JA; Piitulainen E
Thorax; 2008 Dec; 63(12):1091-5. PubMed ID: 18682522
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk in severe alpha-1-antitrypsin deficiency.
Hiller AM; Ekström M; Piitulainen E; Lindberg A; Rönmark E; Tanash H
Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35361631
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of children with α-1 antitrypsin deficiency.
Comba A; Demirbaş F; Çaltepe G; Eren E; Kalayci AG
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):774-778. PubMed ID: 29505478
[TBL] [Abstract][Full Text] [Related]
13. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort.
Clark VC; Marek G; Liu C; Collinsworth A; Shuster J; Kurtz T; Nolte J; Brantly M
J Hepatol; 2018 Dec; 69(6):1357-1364. PubMed ID: 30138687
[TBL] [Abstract][Full Text] [Related]
14. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
15. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.
Mostafavi B; Piitulainen E; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2019; 14():525-530. PubMed ID: 30880942
[TBL] [Abstract][Full Text] [Related]
16. The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34.
Tanash HA; Nystedt-Düzakin M; Montero LC; Sveger T; Piitulainen E
Ann Am Thorac Soc; 2015 Jun; 12(6):807-12. PubMed ID: 25803183
[TBL] [Abstract][Full Text] [Related]
17. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
18. Survival in severe alpha-1-antitrypsin deficiency (PiZZ).
Tanash HA; Nilsson PM; Nilsson JA; Piitulainen E
Respir Res; 2010 Apr; 11(1):44. PubMed ID: 20420704
[TBL] [Abstract][Full Text] [Related]
19. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
Turner AM; Stolk J; Bals R; Lickliter JD; Hamilton J; Christianson DR; Given BD; Burdon JG; Loomba R; Stoller JK; Teckman JH
J Hepatol; 2018 Aug; 69(2):378-384. PubMed ID: 29572094
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in alpha-1-antitrypsin deficiency lung disease-analysis from the German registry.
Fähndrich S; Herr C; Greulich T; Seibert M; Lepper PM; Bernhard N; Lützow C; Vogelmeier C; Bals R
COPD; 2015 May; 12 Suppl 1():58-62. PubMed ID: 25938294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
